Trevi Therapeutics Inc., a clinical-stage biopharmaceutical company, has announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis $(IPF.UK)$. The trial achieved its primary endpoint, showing statistically significant reductions in 24-hour cough frequency across all dose groups, including 108 mg BID and 54 mg BID (p <0.0001) and 27 mg BID (p<0.01), with a 43.3% placebo-adjusted change at the highest dose. Rapid reductions were noted as early as Week 2. Haduvio was generally well-tolerated, with discontinuation rates due to adverse events similar to those in the placebo group. Trevi plans to request an End-of-Phase 2 meeting with the FDA later in the year and intends to initiate a Phase 3 program in the first half of 2026. A conference call and webcast to discuss these results will be held today at 8:30 a.m. ET.